

Quantitative Analysis of Serum Neutralization of Human Immunodeficiency Virus Type 1 from Subtypes A, B, C, D, E, F, and I: Lack of Direct Correlation between Neutralization Serotypes and Genetic Subtypes and Evidence for Prevalent Serum-Dependent Infectivity Enhancement

LEONDIOS G. KOSTRIKIS, YUNZHEN CAO, HELEN NGAI,
JOHN P. MOORE, AND DAVID D. HO*

*Aaron Diamond AIDS Research Center, New York University
School of Medicine, New York, New York 10016*

Received 25 July 1995/Accepted 12 October 1995

Human immunodeficiency virus type 1 (HIV-1) M group strains have been assigned to date to nine distinct genetic subtypes, designated A through I, according to phylogenetic analyses of nucleotide sequences of their *env* or *gag* genes. Whether there is any relationship between phylogenetic subtypes and the neutralization serotypes is not clear, yet defining the nature of any such relationship by mathematical means would be of major importance for the development of globally effective HIV-1 vaccines. We have therefore developed a quantitative method to analyze serum neutralization of HIV-1 isolates and to identify HIV-1 neutralization serotypes. This method involves calculations of the neutralization index, $N^{(i)}$, a newly defined parameter derived from plots generated from in vitro neutralization assays, calculations of pairwise serum-virus vector distances, and cluster analyses. We have applied this approach to analyze three independent neutralization matrices involving primary HIV-1 strains and sera from genetic subtypes A, B, C, D, E, F, and I. Detailed serum and HIV-1 isolate cluster analyses have shown that in general, the identified neutralization serotypes do not directly correlate with HIV-1 genetic subtypes. These results suggest that neutralization serotypes developed during natural HIV-1 infection are not governed by antibodies directed against simple epitopes within gp120 monomers. A significant proportion (28%) of 1,213 combinations of sera and HIV-1 isolates caused serum-dependent infectivity enhancement [negative $N^{(i)}$ values] rather than neutralization. We also noted that negative $N^{(i)}$ values tended to correlate better with certain HIV-1 isolates rather than with HIV-1-positive sera. Syncytium-inducing variants of HIV-1 were slightly more likely than non-syncytium-inducing variants to undergo serum-dependent infectivity enhancement, although the latter variants could clearly be susceptible to enhancement.

Human immunodeficiency virus type 1 (HIV-1) M group strains have been assigned to nine genetic subtypes, designated A through I, on the basis of *env* or *gag* gene nucleotide sequences (1, 3–5, 8, 9, 13, 16, 22–26, 29, 32–35, 44–48, 50, 54, 61). Recently, an additional number of HIV-1 recombinants in *env* and *gag* were also identified (51). The existence of HIV-1 variation on this scale has important implications for understanding the global evolution of HIV-1 and for designing antigenically suitable HIV-1 vaccines based on the induction of neutralizing antibodies. However, HIV-1 neutralization depends on the association of antibodies not only with linear epitopes whose structure might vary in a way predictable from knowledge of genetic subtypes, for example epitopes within the V3 loop, but also with discontinuous epitopes within the monomeric and oligomeric forms of the HIV-1 envelope glycoproteins (10, 18, 19, 41, 43, 57). Additional complex epitopes may also be associated with the icosahedral-symmetry organization of the envelope glycoproteins on the viral surface (14,

15, 49). How subtype-dependent sequence variation might affect the structure and presentation of these complex epitopes is not yet possible to predict from our limited knowledge of envelope tertiary and quaternary structure. An additional complexity is that infection-enhancing antibodies or other factors present in the serum may interfere with the effects of neutralizing antibodies. Therefore, it is not obvious that neutralization serotypes should correspond precisely to the genetic subtypes.

It is, however, important to confirm this because if neutralization efficiency is indeed strongly influenced by the degree of genetic heterogeneity predicted by the subtypes (i.e., if the neutralization serotypes are identical to genetic subtypes), an appropriate vaccine strategy might be to design immunogens based on the predominant genetic variants circulating in any one locale at any one time, similar to the current influenza vaccine strategy. In contrast, if all HIV-1 strains are equally susceptible to serum neutralization (i.e., if there is a single neutralization serotype), a single immunogen might suffice worldwide. Alternatively, if HIV-1 isolates or sera are clustered into specific neutralization serotypes (i.e., if the neutralization serotypes do not directly coincide with the genetic subtypes), an appropriate vaccine strategy might be to tailor

* Corresponding author. Mailing address: Aaron Diamond AIDS Research Center, 455 First Ave., New York, NY 10016. Phone: (212) 725-0018. Fax: (212) 725-1126. Electronic mail address: ho@adarc.nyu.edu.




FIG. 1. Six representative serum neutralization plots from in vitro neutralization assays from viral isolates and sera collected from HIV-1-infected patients in Cyprus. The identification number and genetic subtype of the serum and viral isolate used are indicated at the top of each plot. R is the reciprocal of serum dilution. Error bars represent 1 SD of the mean value ($n = 4$). The dashed lines represent the 50 and 90% neutralization levels.

immunogens based on each of the identified neutralization serotypes, irrespective of the genetic subtypes.

To address this issue, we performed in vitro neutralization assays using HIV-1 isolates and sera from the genetic subtypes A, B, C, F, and I and then analyzed the data by using a newly developed method, here referred to as the neutralization index method (NIM). We then used NIM to analyze the results of more extensive neutralization assays using HIV-1 isolates and sera from subtypes A through E (39), with the goal of identifying all putative neutralization serotypes. The results of our analyses revealed that there are a significant number of HIV-1 isolates that exhibit infectivity enhancement rather than neutralization by most sera tested. Cluster analyses revealed that the putative neutralization serotypes do not directly correspond to the genetic subtypes. Furthermore, except for that from Thai subtype E isolates, the analysis of a data set generated by using only sera selected to have high titers of antibodies reactive with monomeric gp120 showed that there can be some correlation between neutralization serotypes and genetic subtypes under certain circumstances. An additional finding was that these sera did not neutralize HIV-1 isolates better than sera with lower titers to monomeric gp120.

MATERIALS AND METHODS

HIV-1 primary isolates and sera. Twenty-four sera and 14 HIV-1 isolates were obtained by the Aaron Diamond AIDS Research Center from patients in Cyprus (30). Descriptions of the virological and clinical profiles of the study subjects from whom HIV-1 was isolated for use in this study, and of the methods used to determine HIV-1 viral subtypes, have been previously reported (30). Other viral isolates and sera analyzed in this study were obtained from repositories organized by the World Health Organization (WHO) and by the National Institute of Allergy and Infectious Diseases (NIAID). Details of these reagents are found in the accompanying report (39).

Serum neutralizing activity against HIV-1 isolates. Twenty-four sera from HIV-1-infected individuals were analyzed for the ability to neutralize a panel of 14 HIV-1 strains isolated from the same patient cohort. The neutralization assay has been described previously (6, 7, 39, 40). It is important to note that all sera were heat inactivated (56°C for 30 min) before their use in the neutralization assays, to destroy complement and other labile proteins. Peripheral blood mononuclear cells used for experimental and control cultures were from the same donor to minimize variation of virus replication in host cells from different donors.

Serum neutralization parameter. The serum neutralization parameter, N , is defined as follows:

$$N = \frac{[p24]_c - [p24]_e}{[p24]_e} \times 100 \quad (1)$$

where $[p24]$ denotes the HIV-1 p24 antigen concentration measured in each culture, c denotes the p24 antigen value in a control culture, and e denotes the corresponding value in the presence of HIV-1-positive patient serum. Therefore,

N can be equal to or less than 100%. Negative values of N arise when $[p24]_c$ is larger than $[p24]_e$ and indicate that virus infection of the culture in the presence of the serum is greater than that of the control. We analyzed a series of plots describing the variation of N with $x = \log_2(R)$, where R is the reciprocal of serum dilution. Experiments are typically carried out for a serum dilution range of $a \leq x \leq b$. Six representative neutralization plots out of a total of 336 from the Cypriot reagents are shown in Fig. 1.

Serum neutralization index. A neutralization index, $N^{(i)}$, is mathematically defined as follows:

$$N^{(i)} = \int_a^b N(x)dx \quad (2)$$

Under experimental conditions, a finite number of datum points is recorded for different discrete values of x . Let these values be $\{x_i\}_{i=1}^M$, where $x_i = a$ and $x_M = b$. An approximation to equation 2 is easily obtained by numerical quadratures such as the trapezoidal rule. A more accurate value is obtainable, in theory, by polynomial interpolation and analytical evaluation of the resulting integral. However, because of the magnitude of typical experimental errors in this assay (10 to 20%), the advantage of using such a refined procedure is not clear. Therefore, each $N^{(i)}$ value was calculated by using the trapezoidal rule approximation of equation 2 on the basis of six values, $x = 3, 4, 5, 6, 7$, and 8. Calculations using the trapezoidal rule approximation and the above-specified values of x show that the upper bounds of $N^{(i)}$ is 500.

Twenty-four sera were evaluated for their neutralizing or enhancing activities against a panel of 14 HIV-1 primary isolates representing subtypes A, B, C, F, and I. The neutralization index for each serum-virus assay was computed from the experimental data described above. These values are represented in a matrix $(N_{sv}^{(i)})_{s=1,24}$ (see Table 2). Here, we have used matrix notation in which the entry

$N_{sv}^{(i)}$ is the neutralization parameter derived from an assay using serum s and virus v . To compare the calculated $N^{(i)}$ values with the more traditional display of ID_{50} and ID_{90} values (highest serum dilutions that produced ≥ 90 and $\geq 50\%$ inhibition) from neutralization assays (6, 7, 18), we present in Table 1 matrices of the highest R values that produced $N \geq 50\%$ and $N \geq 90\%$ for each element.

We also calculated the $N^{(i)}$ values from neutralization data from sera and HIV-1 isolates obtained from NIAID and WHO presented as ID_{50} and ID_{90} values in the accompanying report (39). These calculations are presented in matrices $(N_{sv}^{(i)})_{s=1,19}$ (Table 3), $(N_{sv}^{(i)})_{s=1,21}$ (Table 4), and $(N_{sv}^{(i)})_{s=1,15}$ (Table 5). The $N^{(i)}$ values from these matrices were calculated by using the trapezoidal rule approximation from five instead of six values ($x = 3, 4, 5, 6$, and 7), and therefore $N^{(i)} \leq 400$.

Serum and virus neutralization cluster analyses. Our cluster analyses and identification of putative sera neutralization serotypes were based on square matrices, $(N_{sv}^{(i)})$, derived as follows. First, the matrix $(N_{sv}^{(i)})$ was standardized by dividing each column by the magnitude of the largest element in that column. This was done to evaluate the relative neutralizing effects of different sera against tested viruses. We alternatively standardized the matrix $(N_{sv}^{(i)})$ by normalizing each column vector to a unit length. Note that both standardization procedures preserve directions but not necessarily lengths. Next, all pairwise vector distances between rows of the standardized $(N_{sv}^{(i)})$ were computed by two different distance definitions: (i) Euclidean distance

$$d_1(\underline{x}, \underline{y}) = \sqrt{\sum_{k=1}^{14} (x_k - y_k)^2}$$

and (ii) Bray-Curtis coefficient

$$d_2(\underline{x}, \underline{y}) = \sum_{k=1}^{14} |x_k - y_k| / \sum_{k=1}^{14} |x_k + y_k|$$

where \underline{x} and \underline{y} are any two standardized vectors. These scalar distance values are represented in square matrices measuring 24 by 24. For cluster analysis and identification of putative HIV-1 isolates' neutralization serotypes, the original matrix $(N_{sv}^{(i)})$ was reversed (columns were reversed into rows) into matrix $(N_{vs}^{(i)})$. From there, the analysis proceeded as explained above. Similar analyses were also performed on the three additional $N^{(i)}$ matrices (Tables 3 to 5) calculated from neutralization data derived by using reagents obtained by the NIAID and WHO (39).

Algorithms written by us and algorithms implemented in BMDP (11) were used to produce distance matrices. Neutralization serotype trees were constructed by using the single-linkage algorithm from BMDP as well as the neighbor-joining and UPGMA clustering algorithms from PHYLIP (12). Consensus clusters generated from all three clustering algorithms, neighbor joining, UPGMA, and single linkage, were considered putative neutralization serotypes. The

identities of neutralization serotypes were investigated by implementing artificial neural network architectures (28, 31).

RESULTS

Neutralizing activities of sera against HIV-1 isolates. In this report, we first describe the neutralizing activities of 24 sera against 14 HIV-1 isolates from subtypes A, B, C, F, and I obtained from HIV-1-infected patients in Cyprus (30). The HIV-1 isolates were derived from subjects at different disease states, from seroconversion to AIDS. There are 4 sera and four HIV-1 isolates from subtype A, 15 sera and eight isolates from subtype B, 1 serum from subtype C, 2 sera and one isolate from subtype F, and 2 sera and one isolate from subtype I.

In Table 1 are presented two values from each neutralization curve, the reciprocals of the traditional ID_{50} and ID_{90} neutralization values, as previously described (6, 7). Additional ID_{50} and ID_{90} neutralization values generated with sera and isolates from subtypes A through E are presented in the accompanying report (39). Consistent with the neutralization data in that report (39), inspection of the ID_{50} and ID_{90} neutralization values derived from assays with the Cypriot samples revealed no obvious subtype-specific patterns of neutralization. Instead, a number of HIV-1 isolates (HO42, HO49, HO04, and HO32) were sensitive to neutralization by most sera, while others (HO43, HO16, HO12, HO11, and HO40) were highly resistant.

We were concerned, however, that drawing definite conclusions from ID_{50} and ID_{90} values alone might be inappropriate. Neutralization curves with uncloned isolates and polyclonal HIV-1⁺ sera are often of irregular shape (Fig. 1). Frequently, the curves level off near the 90% neutralization mark, and their flatness can lead to considerable imprecision in the definition of ID_{90} values. This point is exemplified in Fig. 1a, as only a small variation in the extent of neutralization could significantly shift the position at which the experimental curve intercepts the 90% neutralization mark. Neutralization curves resembling that shown in Fig. 1b are very common, in that 50% but not 90% neutralization is achieved. For this type of curve, ID_{50} values may significantly overestimate the extent of neutralization, but the absence of an ID_{90} value underestimates it, especially when the curve levels off just below the 90% neutralization mark. Many neutralization curves are similar to that shown in Fig. 1c; the biphasic nature reflects the polyclonality of neutralizing human sera. The curve shoulder around the ID_{50} mark creates a significant error in the determination of an ID_{50} value, and 90% neutralization is not achieved, yet significant neutralization has clearly taken place. The neutralization curve displayed in Fig. 1d is frequently observed and illustrates another critical point. Decreasing the serum concentration actually increases the extent of neutralization, so that in an extreme case the ID_{50} value could be greater than the ID_{90} value. The type of neutralization profile exemplified by Fig. 1e creates ambiguities in determining the correct ID_{50} value. Finally, some sera cause significant negative neutralization (infectivity enhancement) of certain isolates at most, if not all, dilutions in the range evaluated (Fig. 1f). Nevertheless, inspection of the ID_{50} and ID_{90} values in Table 1 revealed no consistent subtype-specific patterns of neutralization, in that high values were not concentrated along the diagonals.

$N^{(i)}$. Because of the complex factors revealed by the irregular profiles in a large proportion of the 1,213 neutralization curves that were analyzed to generate the four neutralization matrices, we decided to develop a better method to quantitate the neutralization of uncloned primary HIV-1 isolates by polyclonal sera and to identify any underlying neutralization trends

TABLE 1. Neutralization matrix of sera and primary HIV-1 isolates from subtypes A, B, C, F, and I

Source of serum	R value for ^a :													
	ID ₅₀													
	Subtype A				Primary HIV-1 isolate								Subtype F, HO16	Subtype I, HO32
	HO17	HO34	HO42	HO49	Subtype B									
				HO04	HO11	HO12	HO25	HO27	HO39	HO40	HO43			
Subtype A														
HO17	—	256	256	256	128	—	—	256	64	128	—	—	—	256
HO34	16	128	256	256	128	—	—	256	256	64	—	—	—	256
HO42	32	256	256	128	32	—	—	16	32	64	—	—	—	256
HO49	256	64	256	256	—	—	8	112	—	128	—	—	8	256
Subtype B														
HO04	8	—	256	256	64	32	16	256	256	256	256	—	16	256
HO11	8	—	256	256	256	8	16	256	256	64	16	—	32	256
HO12	—	128	256	256	64	64	16	256	128	256	8	—	—	256
HO25	—	8	256	256	256	8	—	256	256	8	—	—	—	256
HO27	—	256	256	—	256	8	—	128	—	—	—	—	—	256
HO39	—	64	256	128	128	32	—	256	128	256	—	—	—	256
HO40	16	—	256	256	256	16	—	128	256	128	—	—	—	256
HO43	8	256	256	128	128	—	—	—	32	128	—	—	—	256
HO21	—	128	256	256	256	64	16	128	256	256	—	—	—	256
HO28	—	128	—	—	256	—	—	128	—	128	—	—	—	256
HO29	—	256	256	256	128	—	—	128	256	128	—	—	—	256
HO45	8	—	256	256	—	—	—	—	128	256	—	—	—	256
HO46	—	64	256	128	—	—	8	128	128	128	—	—	—	256
HO48	—	256	256	256	256	8	64	256	256	256	32	—	—	256
HO50	16	64	256	256	128	32	8	256	32	32	8	—	—	256
Subtype C,														
HO02	—	16	256	256	256	—	8	256	256	128	32	—	16	256
Subtype F														
HO16 ^b	—	256	256	256	32	—	—	—	64	128	—	—	—	128
HO44	—	128	256	64	64	—	—	—	32	32	—	—	—	256
Subtype I														
HO32	—	—	256	256	256	—	—	256	256	64	—	—	—	256
HO31	32	128	255	256	128	—	—	128	256	256	—	—	—	256

^a Reciprocal of highest serum dilution that produced ≥50% or ≥90% inhibition of in vitro HIV-1 p24 antigen production relative to control cultures. Serum neutralizations with autologous viruses are indicated by boxes. —, no neutralization observed.

^b Plasma specimen.

which could not be discerned by a simple subjective inspection of the ID₅₀ and ID₉₀ values. This method, NIM, essentially relies on a newly defined parameter, $N^{(i)}$, which is defined as the area under each neutralization curve and thus makes an allowance for irregularities in curve shapes. As defined, an $N^{(i)}$ value of 500 (or 400 for the matrices displayed in the accompanying report [39]) represents the maximum extent of neutralization that could be achieved, while smaller values indicate a proportionately lesser extent of neutralization. An $N^{(i)}$ value of zero means that the net neutralization from all serum dilutions evaluated is zero. Of particular note is that a negative $N^{(i)}$ value indicates a net enhancement of virus infectivity, exemplified by Fig. 1f. In Fig. 2, the traditional ID₅₀ values presented in Table 1 are plotted against the corresponding $N^{(i)}$ values calculated from each neutralization curve. The diversity of neutralization curve profiles is evident by the wide distribution of $N^{(i)}$ values corresponding to a particular serum dilution, showing that an ID₅₀ value could reflect a number of different neutralization profiles.

Table 2 displays the $N^{(i)}$ values calculated from the neutralization data derived from the 24 sera and 14 HIV-1 isolates from subtypes A, B, C, F, and I, described initially in Table 1. Inspection of the $N^{(i)}$ values revealed no consistent subtype-specific patterns of neutralization, in that high $N^{(i)}$ values were not concentrated along the diagonal. This finding agrees with

the conclusions derived from inspection of the ID₅₀ and ID₉₀ values in Table 1. However, several underlying neutralization patterns which could not be identified by a simple inspection were detected by cluster analyses of the standardized $N^{(i)}$ values (see Fig. 3; discussed below).

Two HIV-1 isolates, HO11 and HO43, were associated with negative $N^{(i)}$ values with several sera tested (Table 2). These subtype B strains were isolated from two patients who died of AIDS within a year of the blood sampling (30). In contrast, HIV-1 isolates HO34, HO42, HO49, HO04, HO25, HO27, HO39, and HO32 gave relatively high positive $N^{(i)}$ values with most sera. Among the most neutralization-sensitive isolates were HO39, HO49, and HO32.

Tables 3 and 4 display the $N^{(i)}$ values calculated from the neutralization data from 19 sera and 13 HIV-1 isolates from subtypes B, C, and E obtained by NIAID and from 21 sera and 20 HIV-1 isolates from subtypes A through E obtained by WHO. The primary neutralization data are described in the accompanying report (39). In Table 3, HIV-1 isolates 92HT593, 93MW101, and 93TH966 frequently produced positive $N^{(i)}$ values (Table 3), the most neutralization-sensitive isolate being 93MW101. In contrast, nine HIV-1 isolates, 92HT594, 92HT596, 92US711, 91US712, 92US714, 92US715, 93MW960, 93MW099, and 93TH975, gave mostly negative $N^{(i)}$ values; of these isolates, 92HT594, 91US712, and 92HT596 were biologically phe-

TABLE 1—Continued

R value for ^a :													
ID ₉₀													
Primary HIV-1 isolate													
Subtype A				Subtype B								Subtype F, HO16	Subtype I, HO32
HO17	HO34	HO42	HO49	HO04	HO11	HO12	HO25	HO27	HO39	HO40	HO43		
—	—	—	—	—	—	—	—	—	—	—	—	—	—
—	—	—	—	—	—	—	—	—	—	—	—	—	—
16	—	—	—	—	—	—	—	—	—	—	—	8	—
—	—	—	—	—	—	—	—	—	16	—	—	16	64
—	—	—	—	—	—	—	—	—	8	—	—	32	—
—	—	—	—	—	—	—	—	—	32	—	—	—	—
—	—	—	—	—	—	—	—	—	8	—	—	—	—
—	—	—	—	8	—	—	—	—	—	—	—	—	—
—	—	—	—	8	—	—	—	—	—	—	—	—	—
—	—	—	—	—	—	—	—	—	—	—	—	—	32
—	—	—	—	—	—	—	—	—	—	—	—	—	8
—	—	—	—	—	—	—	—	—	—	—	—	—	—
—	256	—	—	16	—	—	—	—	64	—	—	16	16
—	—	—	—	—	—	—	—	—	—	—	—	—	—
—	—	—	—	—	—	—	—	—	—	—	—	—	8
—	64	—	—	—	—	—	—	—	—	—	—	—	—
—	—	—	—	—	—	—	—	—	—	—	—	—	—
—	16	8	—	—	—	—	—	64	16	—	—	—	256

notyped as syncytium-inducing (SI) variants, whereas the other isolates were non-syncytium-inducing (NSI) variants, as determined by an assay of syncytium formation in MT-2 cells (17); the biological phenotype of isolate 93MW099 was not determined. Comparisons of $N^{(i)}$ values between rows revealed no evidence for sera that enhanced infection of most isolates in a serum-specific manner.

In Table 4, neutralization-sensitive isolates include 92UG029, 92TH014, and 92UG005, whereas five HIV-1 isolates, 92BR021, 92BR025, 92UG021, 91UG046, and 92UG024, frequently produced negative $N^{(i)}$ values; of these five isolates, 92UG021, 92UG046, and 92UG024 had the SI phenotype, isolate 92BR021 had the NSI phenotype, and the phenotype of isolate 92BR025 was not determined (62).

Overall, inspection of $N^{(i)}$ values from the three matrices revealed no obvious correlation between high positive $N^{(i)}$ values and individual genetic subtypes. The negative $N^{(i)}$ values are mostly associated with certain HIV-1 isolates of all subtypes, and they do not seem to be directly correlated with sera of any particular subtype. However, there was a moderate correlation between negative $N^{(i)}$ values and biological phenotype, as determined by the ability of isolates to form syncytia in MT-2 cells. Of the 33 HIV-1 isolates obtained from NIAID (Table 3) and WHO (Table 4), 8 were SI variants and 20 were NSI variants, while the phenotypes of 5 isolates are unknown (17, 62). Six of the eight known SI strains (92HT594, 92HT596, 91US712, 92UG021, 92UG046, and 92UG024) more frequently gave negative rather than positive $N^{(i)}$ values with HIV-1-




FIG. 2. ID₅₀ values derived from viral isolates and sera collected from HIV-1-infected patients in Cyprus (Table 1) plotted against the corresponding $N^{(i)}$ values calculated from the neutralization curves (Table 2). The mean $N^{(i)}$ values calculated from $N^{(i)}$ values from each serum dilution are represented by horizontal lines. Positive $N^{(i)}$ values indicate net neutralization, and negative $N^{(i)}$ values indicate net enhancement.

TABLE 2. $N^{(i)}$ values of sera and HIV-1 isolates representing subtypes A, B, C, F, and I

Source of serum	$N^{(i)}$ for indicated primary HIV-1 isolate ^a													Subtype F, HO16	Subtype I, HO32
	Subtype A				Subtype B										
	HO17	HO34	HO42	HO49	HO04	HO11	HO12	HO25	HO27	HO39	HO40	HO43			
Subtype A															
HO17	112	290	397	385	244	8	45	377	336	272	194	28	112	426	
HO34	238	302	359	340	293	-249	106	362	317	272	80	26	114	405	
HO42	216	205	339	194	254	7	106	186	250	263	101	-65	77	403	
HO49	386	278	356	328	224	10	121	304	188	328	102	47	241	431	
Subtype B															
HO04	152	156	370	374	373	183	202	442	348	407	264	91	209	444	
HO11	156	12	360	372	316	3	196	376	360	306	236	35	187	387	
HO12	95	251	353	358	254	260	145	403	300	398	197	-72	129	413	
HO25	123	203	357	334	341	139	30	335	360	197	197	-59	127	389	
HO27	55	281	269	146	258	-17	25	261	175	208	155	-176	99	351	
HO39	141	236	317	262	325	254	160	361	256	354	94	72	77	348	
HO40	191	149	305	277	347	130	63	323	321	365	149	-46	135	330	
HO43	177	342	316	307	216	-40	13	216	252	252	105	7	92	417	
HO21	181	279	263	378	286	228	172	345	371	361	232	52	88	436	
HO28	74	321	215	215	314	-80	-9	292	183	321	162	-84	164	413	
HO29	212	379	373	321	239	64	231	316	344	382	-63	83	-4	437	
HO45	209	109	341	268	226	-386	101	142	152	310	116	-109	53	362	
HO46	52	266	378	277	210	-181	101	300	270	335	177	-76	117	395	
HO48	126	347	374	336	386	37	148	429	356	450	202	63	205	449	
HO50	233	257	374	304	282	28	161	332	216	267	178	-105	190	421	
Subtype C, HO02	98	211	358	354	401	1	204	375	365	364	232	13	188	409	
Subtype F															
HO16 ^b	140	464	314	336	141	1	117	178	265	288	123	11	-60	391	
HO44	149	311	342	239	227	-367	39	69	272	173	145	-2	39	385	
Subtype I															
HO32	89	211	366	306	286	-1,890	29	322	281	282	55	-66	7	399	
HO31	248	423	252	361	313	-310	134	288	470	400	73	58	28	484	

^a Values were calculated as explained in Materials and Methods. Values derived from autologous neutralizations are enclosed by boxes; negative values are in boldface.

^b Plasma specimen.

positive sera, as did 7 of the 20 known NSI strains (92BR021, 92US711, 92US714, 92US715, 93MW960, 93MW965, and 93TH975). The remaining 2 of the 8 SI strains (92UG029 and 92UG001) frequently produced positive $N^{(i)}$ values, as did the remaining 13 of the 20 known NSI strains (92HT593, 93TH966, 92UG031, 92RW009, 92RW008, 92TH014, 92TH026, 92BR020, 92UG005, 92TH006, 92TH009, 92TH022, and 92TH023) (Tables 3 and 4). Thus, given 28 isolates, of which 8 are SI variants and 20 are NSI variants, the probability of having 6 SI variants out of 13 negative $N^{(i)}$ -specific isolates and 2 SI variants out of 15 positive $N^{(i)}$ -specific isolates is 0.058 on the basis of Fisher's exact probability test. Therefore, the SI phenotype is correlated with negative $N^{(i)}$ -specific isolates. Biological phenotyping on the Cypriot HIV-1 isolates (Table 2) was not done, but the HO11, HO40, and HO43 strains are predicted to be the only SI variants, as judged from the presence of positively charged amino acids at positions 11 (R) and 25 (K) in their V3 loops (30, 62); isolates HO11 and HO43 were two of the three isolates in this panel associated with negative $N^{(i)}$ values (Table 2). Thus, SI strains may be more prone to enhancement of infectivity by sera, although NSI strains clearly also have this property.

Cluster analysis of sera and identification of serum neutralization serotypes. Putative serum neutralization serotypes were identified by cluster analysis on standardized $N^{(i)}$ matrices (Fig. 3A, 4A, 5A, and 6A). In this report, we refer to the cluster constructions as serum neutralization trees and to the final clusters of sera as serum neutralization serotypes. The

serum neutralization trees derived by using distance calculations based on either the Euclidean or the Bray-Curtis coefficient were shown to be almost identical, so we present only the neutralization serotype trees based on the Euclidean distance calculations. Figure 3A shows the serum neutralization trees for the Cypriot samples, and Fig. 4A and 5A show the corresponding serum neutralization trees for the NIAID and WHO sera, respectively. Although it is clear that all identified serum neutralization patterns do not correlate with the genetic subtypes, we refrain from making clear-cut partitions of the neutralization trees into a definite number of serotypes because of the relatively limited number of sera and isolates in each matrix. Further analyses similar to those described in this study, including larger matrices of HIV-1 isolates and sera, would be necessary to make definite identifications of HIV-1 neutralization serotypes. Unfortunately, bootstrap values could not be assigned to each of the branch nodes in Fig. 3 to 6 because of the noniterative nature of our quantitative analysis. However, the clusters defined above have been independently confirmed by using iterative artificial neural network architectures (31).

Cluster analysis of HIV-1 isolates and identification of HIV-1 isolate neutralization serotypes. Putative HIV-1 isolate neutralization serotypes were identified by cluster analysis on reverse-standardized $N^{(i)}$ matrices (Fig. 3B, 4B, 5B, and 6B). Similar to the serum neutralization serotype definition, the final clusters of HIV-1 isolates are referred to as HIV-1 isolate neutralization serotypes, and the constructed trees are referred to as HIV-1 isolate neutralization serotype trees. Figure 3B

TABLE 3. $N^{(i)}$ values of sera and HIV-1 isolates representing subtypes B, C, and E

Source of serum	$N^{(i)}$ for indicated primary HIV-1 isolate ^a												
	Subtype B (phenotype)						Subtype C (phenotype)				Subtype E (phenotype)		
	92HT593 (NSI)	92HT594 (SI)	92HT596 (SI)	92US711 (NSI)	91US712 (SI)	92US714 (NSI)	92US715 (NSI)	93MW960 (NSI)	93MW965 (NSI)	93MW101 (ND ^b)	93MW099 (ND)	93TH966 (NSI)	93TH975 (NSI)
Subtype B													
92HT593	330	-58	65	3	305	-4	-324	-14	-175	372	139	149	-5
92HT594	231	-136	-34	-96	-603	-182	-522	-70	-219	346	93	115	-51
92HT596	295	-17	-43	-70	43	-371	-340	-57	-285	336	-47	-17	-119
92HT599	127	-3,011	-41	-69	-1,347	29	315	-143	-215	293	-21	83	40
92US711	140	-3,269	350	-96	-743	68	-82	-118	395	341	145	198	-187
91US712	142	-3,803	-25	-96	-890	-36	-834	-45	400	303	-120	192	-187
92US714	179	-3,647	-35	90	292	-225	-875	-68	393	293	-106	43	-176
92US715	147	-3,770	-30	-27	-216	-194	-700	-141	384	233	-211	61	-244
92US716	132	-3,557	-45	-90	-287	-21	-675	-66	390	215	233	108	-167
Subtype C													
93MW959	226	-3,129	354	-96	-1,373	100	-35	-25	394	287	111	193	-130
93MW960	79	-1,424	226	-96	-1,372	-5	-285	-4	385	347	264	60	-135
93MW965	-1,155	-3,276	-45	-67	-464	-46	364	11	397	277	78	80	-124
93MW101	-2,700	-2,843	245	293	367	-720	-1,111	27	-228	254	118	86	-200
93MW099	-806	-3,559	-44	-78	-76	-476	-629	39	-160	0	72	196	-160
Subtype E													
93TH966	-2,214	-3,741	368	-87	-394	-426	-274	45	12	317	65	117	-240
93TH975	-85	-2,024	224	-91	-181	-621	-827	77	-28	236	-159	238	-30
93TH976	125	-1,882	268	-95	-485	-136	-918	70	-116	263	-239	193	99
93TH301	137	-3,071	-45	69	130	-238	-1,160	-116	-216	138	-286	-21	-180
92TH302	165	-3,165	-45	-96	-788	-204	-620	-68	-285	248	-308	-334	-363

^a Values were calculated from neutralization data presented in Tables 3 and 4 of the accompanying report (39). Values derived from autologous neutralizations are enclosed by boxes; negative values are in boldface. HIV-1 isolates and sera were obtained by NIAID.

^b ND, phenotype not determined.

shows the HIV-1 isolate neutralization trees for the Cypriot samples; Fig. 4B and 5B show the corresponding HIV-1 isolate neutralization trees for the NIAID and WHO isolates, respectively.

Analysis of selected sera and HIV-1 isolates with high anti-gp120 monomer titers. In Table 5, we present the $N^{(i)}$ values derived from sera that were selected from each subtype on the basis of high binding titers to gp120 monomers from the same subtype (39). To assess the effect on neutralization dictated by the selection of sera with high anti-gp120 monomer titers, we calculated and compared the mean $N^{(i)}$ values and the percentage of negative $N^{(i)}$ values from each of the four $N^{(i)}$ matrices. Furthermore, we produced two equivalent versions of a matrix by selecting random pairs from the full set of $N^{(i)}$ values in Tables 3 to 5 by using a pseudorandom number generator algorithm (63).

The mean $N^{(i)}$ value calculated from the high anti-gp120 titer-selected matrix, a total of 210 elements (Table 5), is 22 (standard deviation [SD] = 205), and the percentage of $N^{(i)}$ values that were negative is 40. The mean $N^{(i)}$ value from the original three unselected $N^{(i)}$ matrices (Tables 2 to 4)—a total of 1,003 elements—is 43 (SD = 492), and the percentage of negative $N^{(i)}$ values is 28. It is evident, however, that the large SD value is a result of the high negative $N^{(i)}$ values derived from HIV-1 isolate 92HT594 [mean $N^{(i)}$ is -2,599, $n = 19$] (Table 3). The mean $N^{(i)}$ value calculated from the same three $N^{(i)}$ matrices after excluding the $N^{(i)}$ outlier values derived from this isolate—a total of 984 elements—is 94 (SD = 280), and the percentage of negative $N^{(i)}$ values is 26. The equivalent mean $N^{(i)}$ value calculated from the WHO and NIAID $N^{(i)}$ matrices only [a total of 648 elements by excluding the $N^{(i)}$ outlier values from 92HT594 isolate] is 34 (SD = 300), and the percentage of negative $N^{(i)}$ values is 37. Furthermore, the

mean $N^{(i)}$ values from two matrices created by selecting random pairs from the full set of $N^{(i)}$ values are 65 (SD = 340) and 62 (SD = 362), and the percentages of negative $N^{(i)}$ values are 28 and 30, respectively. Thus, selecting a panel of sera on the basis of high anti-gp120 monomer antibody titers failed to identify sera with statistically significant higher than average neutralization activity and lower than average infection-enhancing activity; if anything, the converse was observed. To investigate whether there was any inverse correlation between anti-gp120 monomer antibody titers and $N^{(i)}$ values, we plotted the midpoint anti-gp120 titer values (39) against the calculated homotypic $N^{(i)}$ values but found no statistically significant correlation relating the two parameters (data not shown).

Phenetic patterns of V3 loop amino acid sequences do not correlate with neutralization serotypes. Phenetic analyses of the amino acid sequences of the V3 loops from 27 Cypriot sequences (30) were performed by using a structure-based amino acid substitution matrix as previously described (29, 56, 61). Inspection of the generated phenogram (data not shown) revealed that phenetic clusters do not correlate with the neutralization serotypes. Similar phenograms were also constructed for the WHO samples (61). A direct correlation between the HIV-1 isolate neutralization serotypes, phenetic patterns of the V3 loop, and genetic subtypes (61) was observed only for the five subtype E HIV-1 strains (92TH006, 92TH023, 92TH009, 92TH022, and 92TH024) from Thailand (Fig. 5B).

DISCUSSION

Our interest in developing NIM to analyze the neutralizing activities of sera against primary HIV-1 isolates from infect-

TABLE 4. $N^{(i)}$ values of sera and HIV-1 isolates representing subtypes A, B, C, D, and E

Source of serum	$N^{(i)}$ for indicated primary HIV-1 isolate ^a									
	Subtype A (phenotype)					Subtype B (phenotype)				Subtype C, 92BR025 (ND)
	92UG029 (SI)	92UG031 (NSI)	92UG037 (ND ^b)	92RW009 (NSI)	92RW008 (NSI)	92TH014 (NSI)	92TH026 (NSI)	92BR020 (NSI)	92BR021 (NSI)	
Subtype A										
92UG029	50	122	-197	118	94	237	159	158	59	-92
92UG031	380	246	251	255	244	126	140	150	-110	149
92UG037	83	318	290	283	250	256	64	-96	-230	-79
92RW009	142	143	117	95	384	205	-15	18	2	-295
92RW008	329	326	383	385	222	333	276	273	224	377
Subtype B										
92TH014	314	135	1	120	219	258	103	1	168	-70
92TH026	343	188	71	170	124	311	7	18	-79	14
92BR020	163	104	23	-169	212	224	16	-41	93	-46
92BR021	32	-46	-63	-508	139	225	-96	-101	-23	-204
92BR023	289	193	266	243	240	268	122	19	182	101
Subtype C, 92BR025	329	166	261	249	200	224	88	-87	194	-55
Subtype D										
92UG001	364	121	-364	-39	253	90	141	32	-49	-21
92UG005	370	163	235	259	220	316	299	229	198	16
92UG021	293	196	-64	-65	297	193	15	127	-304	-68
92UG046	202	63	-142	-50	284	216	-105	-183	-368	-88
92UG024	379	59	-226	-160	128	183	77	4	-170	-27
Subtype E										
92TH006	333	60	50	-96	-180	109	-112	-44	183	-345
92TH009	8	231	265	95	153	155	-23	-23	136	-18
92TH022	319	322	357	205	171	260	10	-105	-44	-255
92TH024	239	127	115	81	99	230	58	107	203	6
92TH023	346	-28	98	3	62	190	-130	-77	-38	-129

^a Values were calculated from neutralization data presented in Tables 1 and 2 of the accompanying report (39). Values derived from autologous neutralizations are enclosed by boxes; negative values are in boldface. HIV-1 isolates and sera were obtained by WHO.

^b ND, phenotype not determined.

ed patients derives from our concern to define the neutralization serotypes of HIV-1 by mathematical means and to understand their relationships with the genetic subtypes. Identification of neutralization serotypes of HIV-1 would have important strategic implications for the development of globally effective HIV-1 vaccines. We began our analysis with calculations of the neutralization index, $N^{(i)}$, a new parameter that we introduced in this report, which is mathematically defined as the area under the neutralization curve bounded by the lowest and the highest serum dilution measurements. Subsequently, we derived all pairwise serum-HIV-1 isolate vector distances from standardized $N^{(i)}$ values, and we performed cluster analyses. The interpretation of neutralization data based on the neutralization index calculation allows the entire data set used for generation of a serum neutralization curve to be taken into account irrespective of the shape of that curve and clearly reveals when infectivity enhancement has occurred. In contrast, recording only ID_{50} and ID_{90} values obscures any evidence for negative neutralization, or infectivity enhancement, which occurs with HIV-1-positive sera and certain isolates. Additionally, recording only two points from the serum neutralization curves generates numerous null values in the final matrices (Table 1), which thwarts further quantitative analyses to identify any underlying neutralization patterns.

Using NIM to analyze the neutralization data presented in this and the accompanying report (39) revealed that the identified neutralization serotypes—serum and HIV-1 isolate neutralization serotypes—do not generally correspond directly to the genetic subtypes. The lack of a direct association between neutralization serotypes and the genetic subtypes suggests that

antibodies to continuous epitopes on gp120, such as those on the V3 loop, are unlikely to be major contributors to the cross-neutralization of primary isolates that can be observed at low levels with some HIV-1-positive sera. If they were, one would expect a direct correlation between the derived neutralization serotypes and either the genetic subtypes or the identified phenetic patterns of the V3 loop; such correlations were not generally observed. Our conclusions concerning neutralization serotypes are also consistent with the observation that strong, subtype-independent neutralization of primary HIV-1 strains can be caused by a number of neutralizing human monoclonal antibodies (60). A direct correlation between the HIV-1 isolate neutralization serotypes and genetic subtypes was observed only for the five subtype E HIV-1 strains (92TH006, 92TH023, 92TH009, 92TH022, and 92TH024) from Thailand (Fig. 5B) (61). The V3 amino acid sequences from these strains were found to cluster together by means of phenetic analysis (61). However, the entire gp120 molecules from Thai subtype E isolates are also genetically (61) and antigenically (42) homogeneous, so the significance of the V3 loop clustering for understanding isolate neutralization subtypes is not absolutely clear. The clustering of Thai subtype E strains as a single neutralization serotype supports the use of immunogens based on the E, rather than B, subtype for vaccine trials in Thailand.

A loose correlation between the genetic subtypes and serum neutralization serotypes was also observed with most sera that were selected for their high anti-gp120 monomer antibody titers (Fig. 6A), although the potencies of the observed neutralizations were not correlated with the anti-gp120 antibody

TABLE 4—Continued

$N^{(i)}$ for indicated primary HIV-1 isolate ^a									
Subtype D (phenotype)					Subtype E (phenotype)				
92UG001 (SI)	92UG005 (NSI)	92UG021 (SI)	92UG046 (SI)	92UG024 (SI)	92TH006 (NSI)	92TH009 (NSI)	92TH022 (NSI)	92TH024 (ND)	92TH023 (NSI)
106	147	2	71	-88	-35	57	89	-211	-8
386	299	-7	55	-153	69	167	252	29	109
86	349	-197	54	28	338	268	344	241	274
76	289	-128	-32	63	379	366	367	373	315
312	389	88	90	209	145	141	202	-33	118
253	278	60	-114	-204	383	386	356	334	337
377	295	45	-35	-562	144	205	241	-557	46
54	166	-142	-21	-267	263	120	323	248	147
-92	26	22	-70	-1,216	-150	-146	112	-224	-20
340	335	-39	-68	-26	-78	-210	-283	-129	-135
338	334	-61	-70	-70	329	344	282	129	194
378	218	85	73	-124	-65	24	142	-57	-237
384	355	13	293	135	185	127	304	212	98
209	120	-65	56	-71	333	319	357	310	282
165	100	-154	10	-3	363	304	356	248	294
338	52	56	26	-278	197	179	226	63	125
287	-28	-96	-103	-94	341	276	293	120	212
132	256	-398	-118	-148	-189	215	177	-202	61
376	355	-61	-130	-245	-92	192	159	180	-69
393	205	397	-120	-229	-59	68	-133	-87	-228
381	154	82	-154	-1,035	386	389	355	383	377

titers. It may be that choosing sera on the basis of particularly high anti-gp120 titers selects for sera rich in antibodies to continuous epitopes such as the V3 loop, but this procedure does not necessarily identify the most strongly neutralizing sera. Overall, our current interpretation is that identified neutralization serotypes are more likely to be influenced by antibodies to complex epitopes, perhaps dependent on the conformation of the envelope glycoproteins in their native form, rather than by linear epitopes. Linear epitopes, such as those on the V3 loop, may significantly contribute to neutralization under certain circumstances, for example with the Thai subtype E isolates or with sera selected for high anti-gp120 antibody titers, but we found no indication that whenever there might be a dominant contribution of V3-directed antibodies to neutralizing activity, this was in any way associated with the strength of that activity.

One of the most surprising features revealed by NIM was that a significant proportion (28% of 1,003) of sera and HIV-1 isolate combinations from all genetic subtypes caused infectivity enhancement rather than neutralization. The magnitude of enhancement was variable, but mostly in the same range as the magnitude of neutralization. Our definition of infectivity enhancement in this study is that a serum-virus combination produces a net negative $N^{(i)}$ value. However, it should be noted that enhancing antibodies counter the effect of neutralizing ones, so relying only on net enhancement [negative $N^{(i)}$ values] to assess the prevalence of enhancing antibodies underestimates their occurrence. It may be more common for enhancing antibodies to only partially counteract neutralizing ones, leading to a reduction in the extent of neutralization that might otherwise have occurred. Sera selected to contain high titers of antibodies reactive with gp120 monomers were, if anything, more likely to cause infectivity enhancement than were un-

selected sera. Furthermore, we observed no correlation between anti-gp120 antibody titers and the $N^{(i)}$ value, a measure of neutralization potency. Our current interpretation of these results is that neither the neutralizing nor the enhancing activity is governed by antibodies directed against gp120 monomers. Alternatively, the serum neutralizing and enhancing infectivity activities may be both gp120 monomer specific but may cancel each other out, wholly or in part, so that no statistically significant net effect is observed.

Enhancing antibodies have been previously demonstrated in vitro in sera from HIV-1-infected patients (20, 21, 36, 37, 52, 53, 59). However, these studies have relied mostly on T-cell line-adapted HIV-1 strains, and there have been few detailed studies on primary virus neutralization by HIV-1-positive sera. Three mechanisms of infectivity enhancement have been documented: Fc-mediated absorption of immune complexes onto the surfaces of target cells (21, 59), an antibody-dependent, complement-mediated enhancement (36, 37), and a gp120 antibody-specific triggering of the HIV-cell fusion reaction (27, 55, 58). The first two mechanisms tend to be mediated most efficiently by antibodies to the ectodomain of the transmembrane glycoprotein gp41, whereas the third mechanism has been shown to be mediated by monoclonal antibodies to the V3 loop and CD4-binding-site-related epitopes on gp120 (27, 55, 58). Mechanistically, this process may resemble soluble CD4-activated fusion, described first for simian immunodeficiency virus and HIV-2 (2, 38). Our observation that sera rich in anti-gp120 antibodies are liable to cause infectivity enhancement may be significant in the context of the anti-gp120 monoclonal antibody-induced fusion mechanism, especially when it is considered that antibodies to both the V3 loop and CD4-binding-site epitopes are highly prevalent in HIV-1-positive sera (41). The potential contributions of the other




FIG. 3. Serum neutralization tree for 24 sera (A) and HIV-1 isolate neutralization tree for 14 HIV-1 isolates (B) from subtypes A, B, C, F, and I. The neutralization serotype relationships were determined on the basis of the calculated pairwise Euclidean distances between vectors from the standardized matrix ($N_{S_i}^{(i)}$) (Table 2) by using the neighbor-joining clustering algorithm.

known enhancement mechanisms should not be discounted, since sera with high anti-gp120 titers may also have relatively abundant antibodies to the gp41 epitopes associated with complement- or Fc-mediated enhancement. However, under the

conditions of our assays, complement-mediated enhancement is unlikely, as all sera were heated to 56°C for 30 min prior to use.

It is evident from the calculated $N^{(i)}$ values (Tables 2 to 4) and from the identified HIV-1 isolates' neutralization sero-




FIG. 4. Serum neutralization tree for 19 sera (A) and HIV-1 isolate neutralization tree for 13 HIV-1 isolates (B) from subtypes B, C, and E. The neutralization serotype relationships were determined on the basis of the calculated pairwise Euclidean distances between vectors from the standardized matrix ($N_{S_i}^{(i)}$) (Table 3) by using the neighbor-joining clustering algorithm.




FIG. 5. Serum neutralization tree for 21 sera (A) and HIV-1 isolate neutralization tree for 20 HIV-1 isolates (B) from subtypes A through E. The neutralization serotype relationships were determined on the basis of the calculated pairwise Euclidean distances between vectors from the standardized matrix ($N_{ST}^{(U)}$) (Table 4) by using the neighbor-joining clustering algorithm. The bracket and asterisk on the right in panel B denote an HIV-1 neutralization serotype formed by the five subtype E HIV-1 strains (92TH006, 92TH023, 92TH009, 92TH022, and 92TH024) from Thailand.

types (Fig. 3B, 4B, and 5B) that the negative $N^{(U)}$ values tend to be isolate and not serum specific. Our analysis showed that although the infectivities of some of these isolates (e.g., 92HT594 and 93TH975) were enhanced by almost all sera tested, several sera (e.g., 92US711 and 93MW965) that enhanced the infectivities of these isolates also neutralized other isolates. This phenomenon parallels what has been observed with human monoclonal antibodies (27, 55, 58). Thus, the nature of the virus isolate may determine whether a particular serum or monoclonal antibody is enhancing or neutralizing. Furthermore, in preliminary studies, we have occasionally observed that sera negative for HIV-1 antibodies can also enhance the infectivities of certain isolates. Thus, a portion of the observed infectivity enhancement by HIV-1-positive sera may

be due to other, as yet undefined mechanisms associated with some non-HIV-1-specific factor(s) (64). Nevertheless, these results suggest that serum-dependent infectivity enhancement may influence HIV-1 pathogenesis *in vivo*.

In summary, we have introduced a new quantitative method, NIM, to analyze the neutralizing or enhancing activities of sera with HIV-1 isolates by mathematical means, and we have shown that the putative neutralization serotypes—serum and isolate neutralization serotypes—are not identical and presently cannot be predicted by knowledge of the genetic subtypes alone. We are not certain about the exact nature of the neutralizing antibodies that govern the identified neutralization serotypes, but we have shown that neutralizing antibodies directed against linear epitopes on gp120 monomers are un-




FIG. 6. (A) Serum neutralization tree for 15 sera from subtypes A through E (Tables 3 and 4) selected to have high titers of antibodies reactive with monomeric gp120 from the same subtype. (B) HIV-1 isolate neutralization tree for 14 HIV-1 isolates from subtypes A through E. The neutralization serotype relationships were determined on the basis of the calculated pairwise Euclidean distances between vectors from the standardized matrix ($N_{ST}^{(U)}$) (Table 5) by using the neighbor-joining clustering algorithm. The brackets on the right in panel A denote three serum neutralization serotypes formed by three subtype B sera (92HT593, 92TH026, and 92HT596), two from Haiti and one from Thailand, three subtype C sera (93MW960, 93MW959, and 93MW965) from Malawi, and three subtype E sera (92TH966, 92TH975, and 92TH024) from Thailand.

TABLE 5. $N^{(i)}$ values of sera from subtypes A, B, C, D, and E selected to have high anti-gp120 monomer titers

Source of serum	$N^{(i)}$ for indicated primary HIV-1 isolate ^a														
	Subtype A (phenotype)			Subtype B (phenotype)			Subtype C (phenotype)			Subtype D (phenotype)			Subtype E (phenotype)		
	92UG031 (NSI)	92RW008 (ND ^b)	92UG037 (ND)	92HT596 (SI)	92TH026 (NSI)	93MW959 (NSI)	93MW960 (NSI)	93MW965 (NSI)	92UG021 (SI)	92UG024 (SI)	92UG046 (SI)	92TH024 (ND)	93TH966 (NSI)	93TH975 (NSI)	
Subtype A															
92UG031	8														
92RW008		-90	-110	42	-389	-3	-11	69	60	40	-20	177	247	-4	
92UG037		224	143	13	-37	458	142	424	14	-25	209	351	456	95	
Subtype B															
92HT593															
92TH026		-7	-274	47	111	71	12	-22	67	86	201	141	202	-157	
92HT596		-33	-453	168	52	38	17	-105	109	51	-78	102	121	-208	
Subtype C															
93MW960															
93MW965															
93MW959															
Subtype D															
92UG046															
92UG021															
92UG024															
Subtype E															
93TH966															
93TH975															
92TH024															

^a Values were calculated from neutralization data presented in the accompanying report (39). Values derived from autologous neutralizations are enclosed by boxes; negative values are in boldface. HIV-1 isolates and sera were obtained from NIAID and WHO.

^b ND, phenotype not determined.

likely to significantly dictate the nature of the neutralization serotypes. Furthermore, serum-dependent infectivity enhancement phenomena were commonly observed in our studies and seem to be isolate rather than serum specific; SI isolates were slightly more likely than NSI isolates to be susceptible to infectivity enhancement. Together, these findings have strategic implications for the development of any globally effective HIV-1 vaccine. Although a more serious obstacle, understanding how to induce by vaccination broadly neutralizing antibodies in the absence of infection-enhancing antibodies, remains, a more comprehensive analysis of serum neutralization of HIV-1 is necessary to make definitive decisions about the exact number and nature of all neutralization serotypes of HIV-1.

ACKNOWLEDGMENTS

We are grateful to D. T. Papageorgiou and Z.-H. Michalopoulou of the Department of Mathematics and Center for Applied Mathematics and Statistics at the New Jersey Institute of Technology for useful discussions and for the use of computer facilities. We thank B. Korber and K. McInnes at the Los Alamos National Laboratory for critical comments on several parts of our study and for assistance in phenetic analyses, F. Gao and B. Hahn for communicating unpublished data on viral phenotypes, L. Qin and J. Leu for experimental assistance, S. Shin for help with data analysis, and W. Chen for assistance with data presentation. We thank the staff of WHO and their collaborators in the Network for HIV Isolation and Characterisation, in particular H. Rüb-samen-Waigmann, B. Gálvao-Castro, C. Wasi, E. Karita, and S. D. K. Sempala, and the NIAID collaborating investigators K. Nelson, P. Miotti, and N. Halsey for providing the serum and virus isolates for this study. We also thank E. Bagdades, D. Dimitriou, and E. Lazarou for providing Cypriot sera and virus isolates used in this study, and we thank R. Connor, E. Delwart and L. Stamatatos for many helpful discussions and for a critical review of the manuscript.

This work was supported by the Aaron Diamond Foundation, by a Pediatric AIDS Foundation Scholar Award (77238-15-PF), and by an Aaron Diamond Foundation Fellowship Award (HRI 817-5332E), awarded to L.G.K., and by NIH awards RO1 AI36082, RO1 AI25541, and NO1 AI35168 (Antigenic Variation of HIV-1 and Related Lenti-viruses).

REFERENCES

- Abimiku, A. G., T. L. Stern, A. Zwandor, P. D. Markham, C. Calef, S. Kyari, W. C. Saxinger, R. C. Gallo, M. Robert-Guroff, and M. S. Reitz. 1994. Subgroup G HIV type 1 isolates from Nigeria. *AIDS Res. Hum. Retroviruses* **10**:1581-1583.
- Allan, J., J. Strauss, and D. Buck. 1990. Enhancement of SIV infection with soluble receptor molecules. *Science* **247**:1084-1088.
- Baskar, P. V., S. C. Ray, R. Rao, T. C. Quinn, J. E. K. Hildreth, and R. C. Bollinger. 1994. Presence in India of HIV type 1 similar to North American strains. *AIDS Res. Hum. Retroviruses* **8**:1039-1041.
- Bobkov, A., R. Cheingsong-Popov, M. Garaev, A. Rzhaniyeva, P. Kaleebu, S. Beddows, M. H. Bachmann, J. I. Mullins, J. Louwagie, W. Janssens, G. van der Groen, F. McCutchan, and J. Weber. 1994. Identification of an env G subtype and heterogeneity of HIV-1 strains in the Russian Federation and Belarus. *AIDS Res. Hum. Retroviruses* **8**:1649-1655.
- Bruce, C., C. Clegg, A. Featherstone, J. Smith, B. Biryahawaho, R. Downing, and J. Oram. 1994. Presence of multiple genetic subtypes of human immunodeficiency virus type 1 proviruses in Uganda. *AIDS Res. Hum. Retroviruses* **10**:1543-1550.
- Cao, Y., A. E. Friedman-Kien, M. Mirabile, X. L. Li, M. Alam, D. Dieterich, and D. D. Ho. 1990. HIV-1 neutralizing antibodies in urine from seropositive individuals. *J. Acquired Immune Defic. Syndr.* **3**:195-199.
- Cao, Y., L. Qin, L. Zhang, J. Safrin, and D. D. Ho. 1995. Virological and immunological characterization of long-term survivors of human immunodeficiency virus type 1 infection. *N. Engl. J. Med.* **332**:201-208.
- Dietrich, U., M. Grez, H. von Briesen, B. Panhans, M. Geinbendorfer, H. Kühnel, J. Maniar, G. Mahambre, W. B. Becker, M. B. Becker, and H. Rüb-samen-Waigmann. 1993. HIV-1 strains from India are highly divergent from prototypic African and US/European strains, but are linked to a South African isolate. *AIDS Res. Hum. Retroviruses* **8**:23-27.
- Dumitrescu, O., M. L. Kalish, S. C. Kliks, C. I. Banea, and J. A. Levy. 1994. Characterization of human immunodeficiency virus type 1 isolates from children in Romania: identification of a new envelope subtype. *J. Infect. Dis.* **169**:281-288.
- Earl, P. L., C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss. 1994. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. *J. Virol.* **68**:3015-3026.
- Engelman, L., S. Fu, J. Frane, and A. Jones. 1992. BMBP (statistical software) version 1. University Press of California, Los Angeles.
- Felsenstein, J. 1993. PHYLIP (phylogeny inference package) version 3.5. Department of Genetics, University of Washington, Seattle.
- Gao, F., L. Yue, S. Craig, C. L. Thornton, D. L. Robertson, F. E. McCutchan, J. A. Bradac, P. M. Sharp, B. H. Hahn, and the WHO Network for HIV Isolation and Characterisation. 1994. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. *AIDS Res. Hum. Retroviruses* **10**:1359-1368.
- Gelderblom, H. R., E. H. S. Hausmann, M. Özel, G. Pauli, and M. A. Koch. 1987. Fine structure of immunodeficiency virus (HIV) and immunolocalization of structural proteins. *Virology* **156**:171-176.
- Gelderblom, H. R., M. Özel, and G. Pauli. 1989. Morphogenesis and morphology of HIV structure-functions relations. *Arch. Virol.* **106**:1-13.
- Grez, M., U. Dietrich, P. Balfe, H. V. Briesen, J. K. Maniar, G. Mahambre, E. L. Delwart, J. I. Mullins, and H. Rüb-samen-Waigmann. 1994. Genetic analysis of human immunodeficiency virus type 1 and 2 (HIV-1 and HIV-2) mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each virus. *J. Virol.* **68**:2161-2168.
- Hahn, B. H. Personal communication.
- Ho, D. D., J. A. McKeating, X. L. Li, T. Moudgil, E. S. Daar, N.-C. Sun, and J. Robinson. 1991. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. *J. Virol.* **65**:489-493.
- Ho, D. D., M. G. Sarngadharan, M. S. Hirsch, R. T. Schooley, T. R. Rota, R. C. Kennedy, T. C. Chan, and V. L. Sato. 1987. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. *J. Virol.* **61**:2024-2028.
- Homsy, J., M. Meyer, and J. A. Levy. 1990. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. *J. Virol.* **64**:1437-1440.
- Homsy, J., M. Meyer, M. Tateno, S. Clarkson, and J. A. Levy. 1989. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. *Science* **244**:1357-1360.
- Jain, M. K., T. J. John, and G. T. Keusch. 1994. A review of human immunodeficiency virus infection in India. *J. Acquired Immune Defic. Syndr.* **7**:1185-1194.
- Janssens, W., L. Heyndrickx, Y. V. de Peer, A. Bouckaert, K. Fransen, J. Motte, G.-M. Gershy-Damet, M. Peeters, P. Piot, and G. van der Groen. 1993. Molecular phylogeny of part of the env gene of HIV-1 strains isolated in Côte d'Ivoire. *AIDS* **8**:21-26.
- Janssens, W., L. Heyndrickx, K. Fransen, J. Motte, M. Peeters, J. N. Nkengasong, P. M. Ndumbe, E. Dalaporte, J.-L. Perret, C. Atende, P. Piot, and G. van der Groen. 1994. Genetic and phylogenetic analysis of env subtypes G and H in Central Africa. *AIDS Res. Hum. Retroviruses* **10**:877-879.
- Janssens, W., L. Heyndrickx, K. Fransen, M. Temmerman, A. Leonaers, T. Ivens, J. Motte, P. Piot, and G. van der Groen. 1994. Genetic variability of HIV type 1 in Kenya. *AIDS Res. Hum. Retroviruses* **10**:1577-1579.
- Kalish, M. L., C.-C. Luo, B. G. Weniger, K. Limpakarnjanarat, N. Young, C.-Y. Ou, and G. Schochetman. 1994. Early HIV type 1 strains in Thailand were not responsible for the current epidemic. *AIDS Res. Hum. Retroviruses* **10**:1573-1575.
- Kliks, S. C., T. Shioda, N. L. Haigwood, and J. A. Levy. 1993. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. *Proc. Natl. Acad. Sci. USA* **90**:11518-11522.
- Kohonen, T. 1990. The self-organizing map. *Proc. IEEE* **78**:1464-1480.
- Korber, B. T. M., K. MaInnes, R. F. Smith, and G. Myers. 1994. Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. *J. Virol.* **68**:6730-6744.
- Kostrikis, L. G., E. Bagdades, Y. Cao, L. Zhang, D. Dimitriou, and D. D. Ho. 1995. Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I. *J. Virol.* **69**:6122-6130.
- Kostrikis, L. G., Z.-H. Michalopoulou, and D. D. Ho. Unpublished results.
- Kuiken, C. L., G. Zwart, E. Baan, R. A. Coutinho, J. A. R. van der Hoek, and J. Goudsmit. 1993. Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic. *Proc. Natl. Acad. Sci. USA* **90**:9061-9065.
- Louwagie, J., F. E. McCutchan, M. Peeters, T. P. Brennan, E. Sanders-Buell, G. A. Eddy, G. van der Groen, K. Fransen, G.-M. Gershy-Damet, R. Deleys, and D. S. Burke. 1993. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. *AIDS* **7**:769-780.

34. **McCutchan, F. E., P. A. Hegerich, T. P. Brennan, P. Phanuphak, P. Singharaj, A. Jugsuddee, P. W. Berman, A. M. Gray, A. K. Fowler, and D. S. Burke.** 1992. Genetic variants of HIV-1 in Thailand. *AIDS Res. Hum. Retroviruses* **8**:1887–1895.
35. **McCutchan, F. E., B. L. P. Ungar, P. Hegerich, C. R. Roberts, A. K. Fowler, S. K. Hira, L. Perine, and D. S. Burke.** 1992. Genetic analysis of HIV-1 isolates from Zambia and an expanded phylogenetic tree for HIV-1. *J. Acquired Immune Defic. Syndr.* **5**:441–449.
36. **Montefiori, D. C.** 1993. In vitro correlates of HIV and SIV humoral immunity and infection enhancement. *AIDS Res. Rev.* **3**:161–180.
37. **Montefiori, D. C.** Role of complement in HIV and SIV pathogenesis and immunity. *In* M. M. Eible et al. (ed.), *Symposium in Immunology. V. Antiviral immunity*, in press. Springer-Verlag, Heidelberg.
38. **Moore, J. P.** 1995. HIV-1 vaccines: back to primary school. *Nature (London)* **376**:115.
39. **Moore, J. P., Y. Cao, J. Leu, L. Qin, B. Korber, and D. D. Ho.** 1996. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. *J. Virol.* **70**:427–444.
40. **Moore, J. P., Y. Cao, L. Qin, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas III, D. R. Burton, and D. D. Ho.** 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. *J. Virol.* **69**:101–109.
41. **Moore, J. P., and D. D. Ho.** 1992. Conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. *J. Virol.* **67**:863–875.
42. **Moore, J. P., F. E. McCutchan, S.-W. Poon, J. Mascola, J. Liu, Y. Cao, and D. D. Ho.** 1994. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. *J. Virol.* **68**:8350–8364.
43. **Moore, J. P., H. Yoshiyama, D. D. Ho, J. E. Robinson, and J. Sodroski.** 1993. Antigenic variation in gp120s from molecular clones of HIV-1 LAI. *AIDS Res. Hum. Retroviruses* **9**:1185–1193.
44. **Morgado, M. G., E. C. Sabino, E. G. Shpaer, V. Bongertz, L. Brigidio, M. D. C. Guimaraes, E. A. Castilho, B. Galvão-Castro, J. I. Mullins, R. M. Hendry, and A. Mayer.** 1994. V3 region polymorphisms in HIV-1 from Brazil: prevalence of subtype B strains divergent from North American/European prototype and detection of subtype F. *AIDS Res. Hum. Retroviruses* **10**:569–576.
45. **Murphy, E., B. Korber, M.-C. Georges-Courbot, B. You, A. Pinter, D. Cook, M.-P. Kieny, A. Georges, C. Mathiot, F. Barre-Sinoussi, and M. Girard.** 1993. Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the Central African Republic. *AIDS Res. Hum. Retroviruses* **9**:997–1006.
46. **Myers, G.** 1994. HIV: between past and future. *AIDS Res. Hum. Retroviruses* **10**:1317–1324.
47. **Nkengasong, J. N., W. Janssens, L. Heyndrickx, K. Fransen, P. M. Ndumbe, J. Motte, A. Leonaers, M. Ngolle, J. Ayuk, P. Piot, and G. van der Groen.** 1994. Genetic subtypes of HIV-1 in Cameroon. *AIDS* **8**:1405–1412.
48. **Ou, C.-Y., Y. Takebe, B. G. Weniger, C.-C. Luo, M. L. Kalish, W. Auwanit, S. Yamazaki, H. D. Gayle, N. L. Young, and G. Schochetman.** 1993. Independent introductions of two major HIV-1 genotypes into distinct high-risk populations in Thailand. *Lancet* **341**:1171–1174.
49. **Özel, M., G. Pauli, and H. R. Gelderblom.** 1988. The organization of the envelope projections on the surface of HIV. *Arch. Virol.* **100**:255–266.
50. **Potts, K. E., M. L. Kalish, C. I. Bandea, G. M. Orloff, M. S. Louis, C. Brown, N. Malanda, M. Kavuka, G. Schochetman, C.-Y. Ou, and W. L. Heyward.** 1993. Genetic diversity of human immunodeficiency virus type 1 strains in Kinshasa, Zaire. *AIDS Res. Hum. Retroviruses* **9**:613–618.
51. **Robertson, D. L., P. M. Sharp, F. E. McCutchan, and B. H. Hahn.** 1995. Recombination in HIV-1. *Nature (London)* **374**:124–126.
52. **Robinson, E., D. C. Montefiori, and W. M. Mitchell.** 1987. A human immunodeficiency virus type 1 (HIV-1) infection enhancing factors in seropositive sera. *Biochem. Biophys. Res. Commun.* **149**:693–699.
53. **Robinson, W. E., D. C. Montefiori, W. M. Mitchell, A. M. Prince, H. J. Alter, G. R. Dreesman, and J. W. Eichberg.** 1989. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection *in vitro* by serum from HIV-1-infected and passively immunized chimpanzees. *Proc. Natl. Acad. Sci. USA* **86**:4710–4714.
54. **Sabino, E. C., E. G. Shpaer, M. G. Morgado, B. T. M. Korber, R. S. Diaz, V. Bongertz, S. Cavalcante, B. Galvão-Castro, J. I. Mullins, and A. Mayer.** 1994. Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. *J. Virol.* **68**:6340–6346.
55. **Schutten, M., A. C. Andeweg, M. L. Bosch, and A. D. M. E. Osterhaus.** 1995. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. *Scand. J. Immunol.* **41**:18–22.
56. **Smith, R. F., and T. F. Smith.** 1992. Pattern-induced multi-sequence alignment (PIMA) algorithm employing secondary structure-dependent gap penalties for use in comparative protein modelling. *Protein Eng.* **5**:35–41.
57. **Stamatatos, L., and C. Cheng-Meyer.** 1995. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. *J. Virol.* **69**:6191–6198.
58. **Sullivan, N., Y. Sun, J. Li, W. Hofmann, and J. Sodroski.** 1995. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. *J. Virol.* **69**:4413–4422.
59. **Takeda, A., C. U. Tuazon, and F. A. Ennis.** 1988. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. *Science* **242**:580–583.
60. **Trkola, A., A. B. Pomaes, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. F. Barbas III, D. R. Burton, D. D. Ho, and J. P. Moore.** 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. *J. Virol.* **69**:6609–6617.
61. **WHO Network for HIV Isolation and Characterisation.** 1994. HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. *AIDS Res. Hum. Retroviruses* **10**:1327–1343.
62. **Wolf, F., E. Hogervorst, J. Goudsmit, E.-M. Fenyö, H. Rübsamen-Waigmann, H. Holmes, B. Galvão-Castro, E. Karita, C. Wasi, S. D. K. Sempala, E. Kuiken, M. Cornelissen, and WHO Network for HIV Isolation and Characterisation.** 1994. Syncytium-inducing and non-syncytium capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. *AIDS Res. Hum. Retroviruses* **10**:1387–1400.
63. **Wolfram, S.** 1991. *Mathematica* (a system for doing mathematics by computer) version 2. The Advanced Book Program, Addison-Wesley Publishing Company, Inc., Redwood City, Calif.
64. **Wu, S.-C., J. L. Spouge, S. R. Conley, W.-P. Tsai, M. J. Merges, and P. L. Nara.** 1995. Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages. *J. Virol.* **69**:6054–6062.